What immunotherapy backbone do you utilize for patients with resectable Stage III melanoma when you offer neoadjuvant therapy?

This is one of the most debated questions in the melanoma community. We personally prefer using single agent anti-PD1 in the neoadjuvant setting based on the results of the SWOG-1801 study. The recently presented data at ESMO 2023 showed a 97% 2-year RFS in patients with complete pathologic response...